"A new consumer-friendly form ( is now available for making reports to MedWatch, the Food and Drug Administration's (FDA) on-line system for collecting information about serious problems with drugs, medical devices and other FDA-"...
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
PALIVIZUMAB - INJECTION
COMMON BRAND NAME(S): Synagis
USES: Palivizumab is used in certain infants and young children to prevent infections of the breathing tubes and lungs that are caused by a certain virus (respiratory syncytial virus-RSV). It is known as a monoclonal antibody, and it works by preventing the growth of RSV. This medication is not used to treat RSV infection.
HOW TO USE: Read the Patient Information Leaflet provided by your doctor or pharmacist before your child starts receiving palivizumab and before each injection. If you have any questions, consult your doctor or pharmacist.
This medication is given into the muscle by a health care professional, usually once a month during RSV season or as directed by your child's doctor. Dosage is based on your child's weight, medical condition, and response to treatment.
For the most benefit from this drug, keep all scheduled medical appointments, and make sure your child receives each prescribed dose of this medication during RSV season. In the northern hemisphere, RSV season is usually November through April. Continue monthly injections even if your child has a RSV infection. Even if your child has been infected with RSV, he or she may become infected again.
A certain heart surgery (coronary artery bypass graft-CABG) can decrease the effectiveness of palivizumab. If your child has this surgery, he or she should receive the next dose of this medication as soon as possible after the surgery, even if it has been less than 1 month since the last injection.
Additional Synagis Information
Synagis - User Reviews
Synagis User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.